STOCK TITAN

Curis Inc - CRIS STOCK NEWS

Welcome to our dedicated news page for Curis (Ticker: CRIS), a resource for investors and traders seeking the latest updates and insights on Curis.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Curis's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Curis's position in the market.

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.14%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.02%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.47%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.82%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.01%
Tags
earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.98%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.91%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.72%
Tags
clinical trial
Curis Inc

Nasdaq:CRIS

CRIS Rankings

CRIS Stock Data

64.07M
4.87M
0.25%
34.85%
0.95%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Lexington

About CRIS

curis is a publicly-traded biotechnology company (nasdaq: cris) focused on the development and commercialization of innovative drug candidates for the treatment of human cancers. curis’s pipeline of drug candidates includes cudc-907, which is currently being investigating in clinical trials in patients with relapsed or refractory diffuse large b-cell lymphoma with alterations in the myc oncogene. curis is also engaged in a broad collaboration with aurigene in the areas of immuno-oncology and precision oncology. as part of this collaboration, curis has exclusive licenses to oral small molecule antagonists of the pd1 and vista pathways, including pdl1/vista antagonist ca-170, and oral small molecule antagonists of the pd1 and tim3 pathways, including pdl1/tim3 antagonist ca-327, as well as to molecules designed to inhibit the irak4 kinase, including ca-4948. ca-170 is currently undergoing testing in a phase 1 trial in patients with advanced solid tumors and lymphomas. ca-4948 is currentl